46 GHP Q3 2024 Cancer diagnosis and treatment is a complex niche of medicine. With the sheer diversity of cancer types and patients’ physiologies, there are a range of treatments available to apply to any given tumour. This is where OncoGenomX comes in to offer pivotal understanding of each tumour’s make-up and which approach will have the greatest effect, maintaining a strong focus on a winning breast cancer treatment algorithm. Through its AI-based software product, PredictionStarTM, every decision-maker in the process is better informed throughout. “At OncoGenomX, our ambition transcends traditional boundaries of product development. We are committed to revolutionising treatment decision support systems for cancer drug developers and oncologists. Our mission is to transform the paradigm of cancer treatment, making it not just personalised but precise, profoundly predictive, and pre-emptively effective.” Under Founder Wolfgang Hackl, OncoGenomX comprises experts with a broad spectrum of career backgrounds and skillsets, including oncology research, prediction modelling, and diagnostic instrument engineering. The team’s shared goal is to make PredictionStarTM a diagnostic routine for all breast cancer patients. It is dedicated to facilitating the quintessential evidence-based cancer treatment methods, and there is no better-equipped team to carry out this mission. PredictionStarTM is the company’s groundbreaking contribution to the world of oncology and therapeutics research. Through machine learning, this software analyses tumour and patient-specific clinical data to provide accurate, highly specific information about the type of cancer present. This affords drug developers deeper insight and the ability to make the best of their budgets while empowering oncologists to tailor unique treatment plans with greater specificity than ever. Ultimately, this drives improved outcomes and lowers overall costs throughout the research and treatment processes alike. As its software improves, the two-pronged approach at the heart of PredictionStarTM will identify the best possible treatment combination while its algorithms mitigate suboptimal decision making. Its capacity to map cancers by biologic mechanisms will render tumours ever more vulnerable to specific, tailored treatments. From the very beginning of its usage, the tool will improve decision making by facilitating innovative healthcare decisions and coursecorrecting generalised or potentially ineffective treatments. “PredictionStarTM breaks new ground in breast cancer drug development, diagnosis, and therapeutic outcomes with its Making oncological treatment decisions is always a tough call. Doing so effectively relies upon years of expertise and a wealth of crucial analysis, but there is always more that can be done to improve that decision making. OncoGenomX is revolutionising cancer treatment with the use of AI -based software, bringing newfound assuredness to every stakeholder in the wider oncological process by enabling accurate pretherapy outcome predictions. For researchers, medical professionals, and patients, its value is immediate, far-reaching, and comfortably earns OncoGenomX the title of Most Innovative Oncology Software Company 2024 – Europe. Oncology’s Groundbreaking AI Solution biologically, pharmacologically, and clinically framed, evidencebased guidance, aiming at targeting the entire cancer – eradicating it completely and preventing metastasis.” Relentless innovation is the goal at OncoGenomX, which aims to develop this already groundbreaking offering with the development of its software’s multitasking sequencing chip. This will enable DNA and RNA sequencing and analysis of gene mutations, as well as providing sophisticated biological and treatment-relevant tumour information. PredictionStarTM is a profoundly valuable contribution to oncology, representing the cutting-edge in investigative cancer treatment improvement. This software places OncoGenomX at the forefront of healthcare innovation, enhancing oncological practice worldwide and leading the charge in life saving technological innovation. Contact: Wolfgang Hackl Company: OncoGenomX Web Address: www.oncogenomx.com Email@ [email protected] Wolfgang Hackl (left), David Demanse (right), Founders.
RkJQdWJsaXNoZXIy MTUyMDQwMA==